Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2024
Event Date: July 3, 2024
Context: The Company entered into a new Credit Agreement to refinance existing debt, pay transaction fees, and fund working capital and general corporate purposes.
Key Financial Metrics and Debt Structure
The filing details a comprehensive refinancing of the Company's credit facilities. The new Credit Agreement establishes the following facilities:
- Initial Term A-1 Loans: $162,000,000
- Delayed Draw Term A-1 Loans: $189,000,000 (Commitment terminates July 28, 2025)
- Initial Term A-2 Loans: $138,000,000
- Delayed Draw Term A-2 Loans: $161,000,000 (Commitment terminates July 28, 2025)
- Revolving Credit Commitments: $310,000,000
- Total Potential Credit Facilities: $860,000,000
Maturities:
- Term A-1 Loans and Revolving Credit: July 3, 2029
- Term A-2 Loans: July 3, 2031
Interest Rates: Variable rates based on the Net Leverage Ratio (Net Consolidated Total Indebtedness to Consolidated EBITDA). Margins range from 1.00% to 2.25% for Base Rate loans and 2.00% to 3.25% for SOFR loans depending on the leverage tier.
Existing Hedging: An interest rate swap on $300,000,000 notional principal remains in place, fixing the SOFR portion at 0.61% through June 2025.
Material Changes Versus Prior Period
The new Credit Agreement replaces the Amended and Restated Credit Agreement dated April 22, 2021. Key changes include:
- Refinancing: All Term A loans and the revolving credit facility under the 2021 agreement were refinanced.
- Extended Maturity: The new Term A-1 and Revolving facilities mature in 2029, and Term A-2 loans mature in 2031, extending the debt profile compared to the prior agreement.
- Amortization Schedule: Initial Term A-1 Loans require quarterly repayments of 0.625% of the initial principal from September 30, 2024, to June 30, 2026, increasing to 1.250% thereafter. Initial Term A-2 Loans require quarterly repayments of 0.625% commencing September 30, 2024.
- Administrative Agent: Coöperatieve Rabobank U.A., New York Branch, replaced Bank of America, N.A. as the Administrative Agent.
Guidance, Outlook, Risks, and Contingencies
Management Commentary: The filing does not provide specific forward-looking financial guidance or earnings outlook. The transaction is described as a strategic refinancing to support ongoing working capital and general corporate purposes.
Risks and Covenants:
- The Credit Agreement is subject to customary affirmative and negative covenants and events of default.
- Interest rates and commitment fees are variable and tied to the Company's Net Leverage Ratio.
- Commitment Fees: Fees on unused revolving commitments range from 0.20% to 0.35% annually based on leverage. A 0.35% annual fee applies to unused Delayed Draw Term Commitments.
- Collateral: The facilities are secured by substantially the same collateral as the previous agreement.
Unusual Items: The Company may receive patronage from Lenders providing Term A-2 Loans, subject to the Lender's discretion and eligibility programs.
Important Facts for Investor Verification
- Verify the Company's current Net Leverage Ratio to determine the applicable interest rate margins and commitment fees under the new agreement.
- Confirm the utilization of the $310,000,000 Revolving Credit Facility and the status of the $350,000,000 in Delayed Draw Term Loans (which must be drawn by July 28, 2025).
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific financial covenants and thresholds that could trigger an event of default.
- Monitor the impact of the quarterly amortization payments (starting September 30, 2024) on the Company's cash flow.
- Assess the effectiveness of the existing $300,000,000 interest rate swap in mitigating interest rate risk through June 2025.